Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
Metrics to compare | CMPX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCMPXPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.9x | −2.4x | −0.5x | |
PEG Ratio | 0.66 | 0.01 | 0.00 | |
Price/Book | 1.9x | 8.4x | 2.6x | |
Price / LTM Sales | 284.7x | 11.2x | 2.9x | |
Upside (Analyst Target) | - | 415.4% | 57.8% | |
Fair Value Upside | Unlock | 3.6% | 10.2% | Unlock |